OBJECTIVES: Innovative reformulation of active pharmaceutical ingredients used to treat psoriasis can produce significant improvements in clinical and patient-reported outcomes. The efficacy and safety of fixed-combination 0.005% calcipotriol plus 0.064% betamethasone dipropionate (Cal/BD) topical therapy in the treatment of patients with psoriasis vulgaris has been established. The aim of this study was to perform a short-term cost-per-responder analysis of Cal/BD aerosol foam versus Cal/BD ointment in the management of adult patients with psoriasis vulgaris of the body (trunk and limbs).

METHODS: Treatment response was defined as a ≥ 75% reduction in Psoriasis Area Severity Index (PASI-75). Data for response rates were taken from the LEO90100-035 clinical trial (NCT01536886) which compared Cal/BD aerosol foam vs Cal/BD ointment. Drug acquisition costs (in 2017 UK pounds) were according to the British National Formulary (per June 2017). Drug costs only were considered, from the UK payer perspective, based upon dosing regimens from the clinical trial. Cost-per-responder at treatment Week 4 was calculated for Cal/BD aerosol foam vs Cal/BD ointment.

RESULTS: Mean CONCLUSIONS: Cal/BD aerosol foam is more cost effective than Cal/BD ointment in patients with psoriasis vulgaris.